Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised,... by Huang, Jing, Prof, Xu, Jianming, Prof, Chen, Yun, MD, Zhuang, Wu, MD, Zhang, Yiping, Prof, Chen, Zhendong, Prof, Chen, Jia, Prof, Zhang, Helong, Prof, Niu, Zuoxing, Prof, Fan, Qingxia, Prof, Lin, Lizhu, Prof, Gu, Kangsheng, Prof, Liu, Ying, MD, Ba, Yi, Prof, Miao, Zhanhui, MD, Jiang, Xiaodong, MD, Zeng, Ming, Prof, Chen, Jianhua, Prof, Fu, Zhichao, MD, Gan, Lu, MD, Wang, Jun, Prof, Zhan, Xianbao, Prof, Liu, Tianshu, Prof, Li, Zhiping, Prof, Shen, Lin, Prof, Shu, Yongqian, Prof, Zhang, Tao, PhD, Yang, Qing, MD, Zou, Jianjun, MD

Get full text

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial by Shi, Yuankai, MD, Zhang, Li, MD, Liu, Xiaoqing, MD, Zhou, Caicun, MD, Zhang, Shucai, MD, Wang, Dong, MD, Li, Qiang, MD, Qin, Shukui, MD, Hu, Chunhong, MD, Zhang, Yiping, MD, Chen, Jianhua, MD, Cheng, Ying, MD, Feng, Jifeng, MD, Zhang, Helong, MD, Song, Yong, MD, Wu, Yi-Long, MD, Xu, Nong, MD, Zhou, Jianying, MD, Luo, Rongcheng, MD, Bai, Chunxue, MD, Jin, Yening, MD, Liu, Wenchao, MD, Wei, Zhaohui, PhD, Tan, Fenlai, MD, Wang, Yinxiang, PhD, Ding, Lieming, MD, Dai, Hong, MD, Jiao, Shunchang, MD, Wang, Jie, MD, Liang, Li, MD, Zhang, Weimin, MD, Sun, Yan, Prof

Get full text